Clinical Trial Update: Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase I safety and pharmacokinetics study of oral Anvylic-3288 in healthy subjects; the trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Anvylic-3288

Snippet

Sponsor: University of Colorado, Denver | Conditions: Schizophrenia | Phase 1 | Status: TERMINATED